179 related articles for article (PubMed ID: 23034028)
21. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Latimer NR; Bell H; Abrams KR; Amonkar MM; Casey M
Cancer Med; 2016 May; 5(5):806-15. PubMed ID: 27172483
[TBL] [Abstract][Full Text] [Related]
22. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
23. Trametinib for patients with advanced melanoma.
Masuda S; Izpisua Belmonte JC
Lancet Oncol; 2012 Oct; 13(10):e409; author reply e409-10. PubMed ID: 23026823
[No Abstract] [Full Text] [Related]
24. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
26. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB; Xia J; Hutchinson K; Ng C; Hucks D; Jia P; Atefi M; Su Z; Branch S; Lyle PL; Hicks DJ; Bozon V; Glaspy JA; Rosen N; Solit DB; Netterville JL; Vnencak-Jones CL; Sosman JA; Ribas A; Zhao Z; Pao W
Cancer Discov; 2012 Sep; 2(9):791-7. PubMed ID: 22798288
[TBL] [Abstract][Full Text] [Related]
27. Whole-genome sequencing and cancer therapy: is too much ever enough?
Garraway LA; Baselga J
Cancer Discov; 2012 Sep; 2(9):766-8. PubMed ID: 22969114
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
[TBL] [Abstract][Full Text] [Related]
29. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
30. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
[TBL] [Abstract][Full Text] [Related]
31. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
32. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
33. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
Menzies AM; Yeh I; Botton T; Bastian BC; Scolyer RA; Long GV
Pigment Cell Melanoma Res; 2015 Sep; 28(5):607-10. PubMed ID: 26072686
[No Abstract] [Full Text] [Related]
34. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
35. Trametinib: first global approval.
Wright CJ; McCormack PL
Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
[TBL] [Abstract][Full Text] [Related]
36. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
37. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
[No Abstract] [Full Text] [Related]
39. [Targeted molecular therapies (except immunotherapy)].
Roux J; Pages C; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
[TBL] [Abstract][Full Text] [Related]
40. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
